Home > Healthcare > Pharmaceuticals > Finished Drug Form > Carglumic Acid Market

Carglumic Acid Market Share

Report ID: GMI8505
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Carglumic Acid Market Share

The carglumic acid industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced product based on different technologies is among a key market strategy.

Carglumic Acid Market Companies

Some of the eminent market participants operating in the carglumic acid industry include:

Apothecon Pharmaceuticals Pvt. Ltd.
Biophore India Pharmaceuticals Pvt Ltd.
Dipharma Francis S.r.l.
Eton Pharmaceuticals
KAVYA PHARMA
MANUS AKTTEVA BIOPHARMA LLP
Merck KGaA
NOVITIUM PHARMA LLC
NURAY CHEMICALS
Recordati Rare Diseases Inc.
Suven Life Sciences Limited.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global carglumic acid industry was valued at around USD 148.6 million in 2023 and is expected to reach around USD 280 million by 2032 at a CAGR of 7.1%, driven by the growing prevalence of metabolic diseases.

The hospital pharmacies segment accounted for a revenue of around USD 77 million in 2023, as they handle the distribution of medications for complex conditions such as hyperammonemia, ensuring that patients receive the necessary treatment.

North America carglumic acid market accounted for USD 60.4 million in 2023, attributed to the rising healthcare expenditure in the region, associated with a growing emphasis on specialty care and rare diseases treatment.

Apothecon Pharmaceuticals Pvt. Ltd., Biophore India Pharmaceuticals Pvt Ltd., Dipharma Francis S.r.l., Eton Pharmaceuticals, KAVYA PHARMA, MANUS AKTTEVA BIOPHARMA LLP, Merck KGaA, NOVITIUM PHARMA LLC, NURAY CHEMICALS, Recordati Rare Diseases Inc., and Suven Life Sciences Limited.